GlassScriptPhysician profile
Dennis R Scheppers
NPI 1013012707
$3,854.04
in general payments reported to CMS, 2019-2025
31 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $631 · 2021: $752 · 2022: $794 · 2023: $310 · 2024: $399 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $586.50 | 2019-2024 | Farxiga, Tezspire |
| Abbvie INC. | $385.64 | 2021-2025 | |
| Boston Scientific Corporation | $362.44 | 2024-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Watchman Access System |
| Pfizer INC. | $355.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.33 | 2019-2022 | |
| Lilly USA, LLC | $263.05 | 2019-2024 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $249.36 | 2020-2023 | Livalo, Seglentis |
| Novo Nordisk INC | $162.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $137.70 | 2019-2023 | Verquvo |
| Amarin Pharma, INC. | $113.12 | 2019-2022 | |
| Amgen INC. | $112.75 | 2019-2023 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $112.22 | 2022-2024 | Trelegy Ellipta |
| Radius Health, INC. | $73.89 | 2019-2023 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $62.13 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $61.75 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.59 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.41 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.26 | 2022 | |
| Allergan, INC. | $51.10 | 2019-2020 | |
| Insmed, INC. | $50.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.04 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $33.30 | 2021 | |
| Ucb, INC. | $29.07 | 2024 | Nayzilam |
| Otsuka America Pharmaceutical, INC. | $25.33 | 2023 | Rexulti |
| Biocryst Pharmaceuticals, INC. | $24.45 | 2020 | |
| Horizon Therapeutics Plc | $23.64 | 2019 | |
| Corcept Therapeutics | $22.45 | 2021 | |
| Eisai INC. | $21.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.99 | 2019 | |
| Abbott Laboratories | $19.82 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $17.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Scheppers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.